Trevena found using ticker (TRVN) now have 4 analysts covering the stock with the consensus suggesting a rating of ‘Buy’. The target price ranges between 6 and 5 with the average target price sitting at 5.25. With the stocks previous close at 2.17 this would indicate that there is a potential upside of 141.9%. The 50 day moving average now sits at 2.35 and the 200 day MA is 2.38. The company has a market capitalisation of $328m. Company Website: http://www.trevena.com
Trevena, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its product candidates include Oliceridine injection, a G protein biased mu-opioid receptor (MOR) ligand that has completed Phase III clinical trials for the management of moderate-to-severe acute pain where intravenous administration is warranted; TRV250, a G protein biased delta-opioid receptor agonist that has completed Phase I clinical study for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR that has completed Phase I clinical study for the treatment of moderate-to-severe acute and chronic pain; TRV027 for the treatment of acute heart failure; and TRV045, a novel S1P modulator for managing chronic pain. The company has a collaboration with Imperial College London to evaluate Trv027 in Covid-19 patients. Trevena was founded in 2007 and is headquartered in Chesterbrook, Pennsylvania.